Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

Y0001017

Methylphenidate hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

threo-Methyl α-phenyl-α-(2-piperidyl)acetate hydrochloride, Ritalin hydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C14H19NO2 · HCl
Número de CAS:
298-59-9
Peso molecular:
269.77
Número MDL:
MFCD00058191
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831220
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

methylphenidate

fabricante / nombre comercial

EDQM

control farmacológico

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

aplicaciones

pharmaceutical (small molecule)

formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

Cl[H].COC(=O)C(C1CCCCN1)c2ccccc2

InChI

1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H

Clave InChI

JUMYIBMBTDDLNG-UHFFFAOYSA-N

Información sobre el gen

human ... SLC6A2(6530) , SLC6A3(6531)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Methylphenidate hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Panayotis K Thanos et al.
Pharmacology, biochemistry, and behavior, 131, 143-153 (2015-02-03)
Most animal studies using methylphenidate (MP) do not administer it the same way it is administered clinically (orally), but rather by injection, resulting in an altered pharmacokinetic profile (quicker and higher peak concentrations). We evaluated several oral-dosing regimens in rats
Britahny M Baskin et al.
Pharmacology, biochemistry, and behavior, 131, 51-56 (2015-02-04)
Past research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder showed that adolescent methylphenidate treatment enhanced cocaine abuse risk in SHR during adulthood. The acquisition of cocaine self-administration was faster, and cocaine dose-response functions were shifted upward
Chloe J Jordan et al.
Drug and alcohol dependence, 140, 25-32 (2014-05-09)
Attention-deficit/hyperactivity disorder (ADHD) is often comorbid with cocaine abuse. Controversy exists regarding long-term consequences of ADHD medications on cocaine abuse liability. Whereas childhood methylphenidate treatment may be preventative, methylphenidate in teens appears to further increase later cocaine abuse risk. In
Craige C Wrenn et al.
Neuroscience letters, 585, 109-113 (2014-11-30)
Fragile X syndrome (FXS), a disorder caused by a mutation in the FMR1 gene, is often associated with Attention Deficit Hyperactivity Disorder (ADHD). Common treatments for the hyperactivity often seen in ADHD involve the use of stimulants and α2-adrenergic agonists.
Alexander Frolov et al.
Journal of neurophysiology, 113(1), 369-379 (2014-10-17)
The nucleus accumbens (NAc) has been shown to play a key role in the brain's response to methylphenidate (MPD). The present study focuses on neuronal recording from this structure. The study postulates that repetitive exposure to the same dose of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico